Oncogene-mediated metabolic gene signature predicts breast cancer outcome

[1]  J. Brooks,et al.  MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer , 2021, Scientific Reports.

[2]  J. Brooks,et al.  Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer , 2021, Cancer Research.

[3]  Yingying Xu,et al.  Metabolic Reprogramming in Triple-Negative Breast Cancer , 2020, Frontiers in Oncology.

[4]  Chenfang Dong,et al.  Metabolic reprogramming in triple-negative breast cancer , 2020, Cancer biology & medicine.

[5]  J. Brooks,et al.  Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1 , 2020, Proceedings of the National Academy of Sciences.

[6]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[7]  H. Shen,et al.  Dysregulation of adenosine kinase isoforms in breast cancer , 2019, Oncotarget.

[8]  P. Tonellato,et al.  A Unique Morphological Phenotype in Chemoresistant Triple-Negative Breast Cancer Reveals Metabolic Reprogramming and PLIN4 Expression as a Molecular Vulnerability , 2019, Molecular Cancer Research.

[9]  Tanya Stoyanova,et al.  Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies , 2019, Molecular Cancer Therapeutics.

[10]  J. Gray,et al.  Targeting Trop-2 in solid tumors: future prospects , 2019, OncoTargets and therapy.

[11]  A. Bardia,et al.  Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer , 2019, The New England journal of medicine.

[12]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[13]  Jose Manuel Rodriguez,et al.  SanXoT: a modular and versatile package for the quantitative analysis of high-throughput proteomics experiments , 2018, Bioinform..

[14]  D. Goldenberg,et al.  The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target , 2018, Oncotarget.

[15]  Jun Yu Li,et al.  Metabolomics of oncogene-specific metabolic reprogramming during breast cancer , 2018, Cancer & metabolism.

[16]  J. Pouysségur,et al.  Metabolic Plasiticy in Cancers—Distinct Role of Glycolytic Enzymes GPI, LDHs or Membrane Transporters MCTs , 2017, Front. Oncol..

[17]  Z. Dai,et al.  Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas , 2017, Cancer management and research.

[18]  J. Pouysségur,et al.  Disrupting glucose-6-phosphate isomerase fully suppresses the “Warburg effect” and activates OXPHOS with minimal impact on tumor growth except in hypoxia , 2017, Oncotarget.

[19]  Xing Li,et al.  High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. , 2016, Breast.

[20]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[21]  E. Fukusaki,et al.  Two isoforms of TALDO1 generated by alternative translational initiation show differential nucleocytoplasmic distribution to regulate the global metabolic network , 2016, Scientific Reports.

[22]  Y. Yen,et al.  Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker , 2016, Oncology reports.

[23]  P. Zeng,et al.  Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis , 2016, Scientific Reports.

[24]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[25]  Lei Duan,et al.  Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma , 2016, International journal of experimental pathology.

[26]  J. Locasale,et al.  Correction to: 'The Warburg Effect: How Does it Benefit Cancer Cells?': [Trends in Biochemical Sciences, 41 (2016) 211]. , 2016, Trends in biochemical sciences.

[27]  Hailin Tang,et al.  The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer , 2016, Scientific Reports.

[28]  Yan Zhou,et al.  Trop2 is overexpressed in gastric cancer and predicts poor prognosis , 2015, Oncotarget.

[29]  P. Zhao,et al.  Clinical investigation of TROP-2 as an independent biomarker and potential therapeutic target in colon cancer. , 2015, Molecular medicine reports.

[30]  Edmund A. Rossi,et al.  Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) , 2015, Oncotarget.

[31]  B. Bonavida,et al.  Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications , 2015, Genes & cancer.

[32]  K. Wennerberg,et al.  Bioluminescent cell-based NAD(P)/NAD(P)H assays for rapid dinucleotide measurement and inhibitor screening. , 2014, Assay and drug development technologies.

[33]  M. Pedriali,et al.  Trop-2 Is a Determinant of Breast Cancer Survival , 2014, PloS one.

[34]  Concha Gil,et al.  General statistical framework for quantitative proteomics by stable isotope labeling. , 2014, Journal of proteome research.

[35]  L. Carey,et al.  The management of early-stage and metastatic triple-negative breast cancer: a review. , 2013, Hematology/oncology clinics of North America.

[36]  Thierry Rème,et al.  Modeling risk stratification in human cancer , 2013, Bioinform..

[37]  J. Bergh,et al.  Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis , 2013, Genome Biology.

[38]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[39]  Zhenqing Feng,et al.  Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. , 2013, Experimental and molecular pathology.

[40]  Jiaoti Huang,et al.  Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. , 2012, Genes & development.

[41]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[42]  Benjamin Haibe-Kains,et al.  DNA methylation profiling reveals a predominant immune component in breast cancers , 2011, EMBO molecular medicine.

[43]  Chris Sander,et al.  18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. , 2011, Cancer research.

[44]  A. Huang,et al.  Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization , 2011, BMC Cancer.

[45]  Daniel Birnbaum,et al.  A gene expression signature identifies two prognostic subgroups of basal breast cancer , 2011, Breast Cancer Research and Treatment.

[46]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[47]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[48]  Peter Regitnig,et al.  Genomic index of sensitivity to endocrine therapy for breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  G. Sprenger,et al.  Transaldolase: from biochemistry to human disease. , 2009, The international journal of biochemistry & cell biology.

[50]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[51]  J. Yun,et al.  Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer , 2009, International Journal of Colorectal Disease.

[52]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[53]  R Margreiter,et al.  TROP2 expression as prognostic marker for gastric carcinoma , 2008, Journal of Clinical Pathology.

[54]  S. Alberti,et al.  A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. , 2008, Cancer research.

[55]  R Margreiter,et al.  High expression of TROP2 correlates with poor prognosis in pancreatic cancer , 2008, British Journal of Cancer.

[56]  Michael Rasse,et al.  TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity , 2008, Modern Pathology.

[57]  Yudi Pawitan,et al.  Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study , 2006, BMC medicine.

[58]  Katsuhiko Yanaga,et al.  Clinical Significance of TROP2 Expression in Colorectal Cancer , 2006, Clinical Cancer Research.

[59]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Ambrus,et al.  Silencing of human c-myc oncogene expression by poly-DNP-RNA. , 2005, Oligonucleotides.

[61]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[62]  H. Matsubara,et al.  Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma , 2004, International journal of cancer.

[63]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[64]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[65]  Kathryn S. Lilley,et al.  MSnbase-an R/Bioconductor package for isobaric tagged mass spectrometry data visualization, processing and quantitation , 2012, Bioinform..

[66]  P. Sullivan,et al.  Genetic variation in Transaldolase 1 and risk of squamous cell carcinoma of the head and neck. , 2008, Cancer detection and prevention.